Efficacy and safety of Tocilizumab, plasmapheresis and their combination in severe COVID-19: A randomized clinical trial.

Autor:	Gholinataj jelodar, Mohsen1,2 (AUTHOR), Rafieian, Shahab3 (AUTHOR), Saghafi, Fatemeh4 (AUTHOR), Hadad zedegan, Navid2 (AUTHOR), Birjandi, Behnaz2 (AUTHOR), Rafieian, Shiva2 (AUTHOR), Allah dini, Azadeh2 (AUTHOR), Dehghanpour, Hanieh2 (AUTHOR), Khalaj, Fatemeh2 (AUTHOR), Zare, Samira2 (AUTHOR), Dehghan Chenari, Hanieh2 (AUTHOR), Hajimaghsoudi, Majid2 (AUTHOR), Mojtaba Sohrevardi, Seyed4 (AUTHOR), Mirzaei, Samaneh1,2 (AUTHOR) mirzaeis@ssu.ac.ir, Jamialahmadi, Tannaz5,6 (AUTHOR), Atkin, Stephen L.7 (AUTHOR), Sahebkar, Amirhossein6,8,9,10 (AUTHOR)
Zdroj:	International Immunopharmacology. Feb2023, Vol. 115, pN.PAG-N.PAG. 1p.
Databáze:	Academic Search Ultimate
Externí odkaz:	Zobrazit plný text záznamu Full Text from ScienceDirect